Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data

Toxicology

Volumn 321, Issue 1, 2014, Pages 62-72

  Zhu, Xiao ^a   Kruhlak, Naomi L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug induced liver injury; Post market safety; Predictive toxicology; QSAR

Indexed keywords

LIVER ENZYME;

ARTICLE; BILE DUCT DISEASE; CALIBRATION; CHOLESTASIS; CLASSIFICATION ALGORITHM; DATA BASE; HUMAN; INFORMATION PROCESSING; LIVER INJURY; LIVER TOXICITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SAFETY; WORKFLOW;

DRUG-INDUCED LIVER INJURY; POST-MARKET SAFETY; PREDICTIVE TOXICOLOGY; QSAR;

ALGORITHMS; AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASCORBIC ACID; BILE DUCT DISEASES; CALIBRATION; CHOLESTASIS; DATA MINING; DATABASES, FACTUAL; DRUG LABELING; DRUG-INDUCED LIVER INJURY; ENDPOINT DETERMINATION; HUMANS; LEVOFLOXACIN; LIVER; NAPROXEN; PRODUCT SURVEILLANCE, POSTMARKETING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS; VITAMINS;

EID: 84899858598     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.03.009     Document Type: Article

References (55)

1. Adikwu E., Deo O. Hepatoprotective effect of vitamin C (ascorbic acid). Pharmacol. Pharm. 2013, 4(1):13.
2. Ahmed I., Haramburu F., et al. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. Stat. Med. 2009, 28(13):1774-1792.
3. Al-Attar A.M. Hepatoprotective influence of vitamin C on thioacetamide-induced liver cirrhosis in Wistar male rats. J. Pharmacol. Toxicol. 2011, 6:16.
4. Almenoff J.S., DuMouchel W., et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol. Drug Saf. 2003, 12(6):517-521.
5. Almenoff J.S., LaCroix K.K., et al. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf. 2006, 29(10):875-887.
6. Aronson J.K., Dukes M.N.G. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions 2006, Elsevier, Amsterdam, Boston.
7. Awadalla E.A. Efficacy of vitamin C against liver and kidney damage induced by paraquat toxicity. Exp. Toxicol. Pathol. 2012, 64(5):431-434.
8. Basile C., Mascia E. Dihydropyridine calcium channel blockers: a rare and reversible cause of hepatotoxicity with cholestasis in a CAPD patient. Nephrol. Dial. Transplant. 1999, 14(11):2776-2777.
9. Boelsterli U.A. Mechanisms underlying the hepatotoxicity of nonsteroidal anti-inflammatory drugs. Drug-induced Liver Disease 2003, 345-375. Marcel Dekker, New York/Basel. N. Kaplowitz, L.D. DeLeve (Eds.).
10. Bonacini M., Louie S., et al. Hepatic injury from antiviral agents. Drug-induced Liver Disease 2003, 519-548. Marcel Dekker, New York. N. Kaplowitz, L.D. DeLeve (Eds.).
11. Brown E.G., Wood L., et al. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999, 20(2):109-117.
12. Chen M., Vijay V., et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discovery Today 2011, 16(15-16):697-703.
13. Chen Y., Guo J.J., et al. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Ann. Pharmacother. 2008, 42(12):1791-1796.
14. Cooper J.A., Saracci R., et al. Describing the validity of carcinogen screening tests. Br. J. Cancer 1979, 39(1):87-89.
15. Deshpande G., Gogolak V., et al. Data mining in drug safety: review of published threshold criteria for defining signals of disproportionate reporting. Pharm. Med. 2010, 24(1):37-43.
16. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Statistician 1999, 53(3.).
17. Elashoff M., Matveyenko A.V., et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141(1):150-156.
18. Evans S.J., Waller P.C., et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 2001, 10(6):483-486.
19. Fontana R.J., Watkins P.B., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009, 32(1):55-68.
20. Fourches D., Barnes J.C., et al. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem. Res. Toxicol. 2010, 23(1):171-183.
21. Gale E.A. Collateral damage: the conundrum of drug safety. Diabetologia 2009, 52(10):1975-1982.
22. Ghabril M., Chalasani N., et al. Drug-induced liver injury: a clinical update. Curr. Opin. Gastroenterol. 2010, 26(3):222-226.
23. Goldman S.A. Limitations and strengths of spontaneous reports data. Clin. Ther. 1998, 20(Suppl. C):C40-C44.
24. Gupta N.K., Lewis J.H. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment. Pharmacol. Ther. 2008, 28(9):1021-1041.
25. Hauben M. Early postmarketing drug safety surveillance: data mining points to consider. Ann. Pharmacother. 2004, 38(10):1625-1630.
26. Hauben M., Reich L., et al. 'Extreme duplication' in the US FDA Adverse Events Reporting System database. Drug Saf. 2007, 30(6):551-554.
27. Ho C.C., Chen Y.C., et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin. Infect. Dis. 2009, 48(11):1526-1533.
28. Hoofnagle J.H., Serrano J., et al. LiverTox: a website on drug-induced liver injury. Hepatology 2013, 57(3):873-874.
29. Howes L.G., Kostner K. The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin. Investig. Drugs 2007, 16(10):1509-1516.
30. Jaeschke H. Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?. Toxicol. Sci. 2007, 97(1):1-3.
31. Jones M., Nunez M. Liver toxicity of antiretroviral drugs. Semin. Liver Dis. 2012, 32(2):167-176.
32. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4(6):489-499.
33. Lewis W., Day B.J., et al. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2003, 2(10):812-822.
34. Lopez-Gonzalez E., Herdeiro M.T., et al. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009, 32(1):19-31.
35. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22(4):719-748.
36. Matthews E.J., Ursem C.J., et al. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 2009, 54(1):23-42.
37. Mendrick D.L., Daniels K.K. Biomarkers of drug-induced adverse events. Expert Rev. Clin. Pharmacol. 2007, 1(1):81-91.
38. Moride Y., Haramburu F., et al. Under-reporting of adverse drug reactions in general practice. Br. J. Clin. Pharmacol. 1997, 43(2):177-181.
39. Mosby Mosby's Drug Consult 2007, St. Mosby, Louis, MO.
40. Orman E.S., Conjeevaram H.S., et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin. Gastroenterol. Hepatol. 2011, 9(6):517-523. e513.
41. Ozkan F., Gunduz S.G., et al. The protective role of ascorbic acid (vitamin C) against chlorpyrifos-induced oxidative stress in Oreochromis niloticus. Fish Physiol. Biochem. 2012, 38(3):635-643.
42. Paterson J.M., Mamdani M.M., et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ 2012, 184(14):1565-1570.
43. Rouse R., Siwy J., et al. Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS One 2012, 7(4):e34606.
44. Smythe M.A., Umstead G.S. Phenytoin hepatotoxicity: a review of the literature. DICP 1989, 23(1):13-18.
45. Suzuki A., Andrade R.J., et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010, 33(6):503-522.
46. Szarfman A., Machado S.G., et al. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002, 25(6):381-392.
47. Szarfman A., Tonning J.M., et al. Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy 2004, 24(9):1099-1104.
48. Tall A.R., Yvan-Charvet L., et al. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler. Thromb. Vasc. Biol. 2007, 27(2):257-260.
49. Teo Y.L., Ho H.K., et al. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat. Rev. 2013, 39(2):199-206.
50. Tolosa E., Marti M.J., et al. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998, 50(6 (Suppl. 6)):S2-S10. discussion S44-18.
51. Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol. 2011, 8(4):202-211.
52. Ursem C.J., Kruhlak N.L., et al. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: Use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 2009, 54(1):1-22.
53. Utsunomiya K., Ikeda Y. Beneficial effect of alacepril, a new angiotensin-converting enzyme inhibitor on albuminuria and glycemic state: an open multicenter trial. Alacepril Study Group. J. Diabet. Complications 1991, 5(2-3):165-166.
54. Yang X., Freeman J., et al. Data mining in pharmacovigilance practice: which algorithm to use?. Drug Saf. 2008, 31(10):885.
55. Zimmerman H.J. Drug-induced liver disease. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver 1999.